BioCentury | Jan 14, 2021
Deals

Jan. 13 Quick Takes: Takeda, KSQ enter immunotherapy deal; plus Taysha, Cardea, Esperion-Serometrix, Paion-La Jolla and more

...disclosed IND timelines.Paion gains European rights to two La Jolla drugsLa Jolla Pharmaceutical Co. (NASDAQ:LJPC) granted Paion AG...
...for $22.5 million up front and up to $109.5 million in milestones, plus double-digit royalties. Paion...
BioCentury | Jan 29, 2020
Company News

Jan. 28 Company Quick Takes: Kite, Alkermes, Regeneron-Sanofi, Incyte, NantHealth-NantOmics, Sorrento, MicroCures, Paion-Mundipharma

...research from Albert Einstein College of Medicine. Paion, Mundipharma gain Japan approval Anerem remimazolam from Paion AG...
...Pharmaceuticals Inc. Sanofi Incyte Corp. Interleukin-4 (IL-4) receptor (IL-4R) (IL-4RA) (CD124) Janus kinase-1 (JAK-1) Janus kinase-2 (JAK-2) Mu opioid receptor (MOR) (OPRM1) MicroCures Sorrento FL2 paion...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...data 2H19 Orphazyme A/S (CSE:ORPHA) Arimoclomol Niemann-Pick disease type C Phase II/III final data 1Q19 Paion AG...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...Durect Corp. (NASDAQ:DRRX) Remoxy oxycodone extended release Moderate to severe chronic pain PDUFA date 8/7/18 Paion AG...
BioCentury | Nov 17, 2017
Clinical News

Paion's remimazolam meets in Phase III trial for procedural sedation

...in the double-blind, U.S. trial include time to discharge and recall of procedure. Last year, Paion...
...of Cosmo Pharmaceuticals N.V. (SIX:COPN) exclusive, U.S. rights to develop and commercialize remimazolam. In 2018, Paion...
...A receptor modulator (see BioCentury, July 18, 2016 ). Cosmo Pharmaceuticals N.V. (SIX:COPN), Dublin, Ireland Paion AG...
BioCentury | Jul 18, 2016
Company News

Paion, Cosmo deal

...subsidiary exclusive U.S. rights to develop and commercialize remimazolam, an ultra-short-acting GABA A receptor modulator. Paion...
...the drug’s approval and for approval of additional indications in general anesthesia and ICU sedation. Paion...
...Paion said that Cosmo expects to file a remimazolam NDA at the end of 2017. Paion AG...
BioCentury | Dec 14, 2015
Clinical News

Remimazolam: Phase III started

...midazolam arm will receive a 1 mg initial dose followed by 0.5 mg top-up doses. Paion AG...
BioCentury | Jul 25, 2015
Company News

Management tracks

...Mologen AG (Xetra:MGN) named Mariola Soehngen CEO, effective Nov. 1. Soehngen will remain CMO at Paion AG...
BioCentury | Jun 22, 2015
Clinical News

Remimazolam: Phase III started

...bronchoscopies. Patients will receive 5 mg remimazolam for induction and 2.5 mg top-ups for maintenance. Paion AG...
BioCentury | Apr 13, 2015
Clinical News

Remimazolam: Phase III started

...Pharmaceutical Co. Ltd. , Seoul, South Korea Humanwell Healthcare Group Co. Ltd. (Shanghai:600079), Wuhan, China Paion AG...
Items per page:
1 - 10 of 182
BioCentury | Jan 14, 2021
Deals

Jan. 13 Quick Takes: Takeda, KSQ enter immunotherapy deal; plus Taysha, Cardea, Esperion-Serometrix, Paion-La Jolla and more

...disclosed IND timelines.Paion gains European rights to two La Jolla drugsLa Jolla Pharmaceutical Co. (NASDAQ:LJPC) granted Paion AG...
...for $22.5 million up front and up to $109.5 million in milestones, plus double-digit royalties. Paion...
BioCentury | Jan 29, 2020
Company News

Jan. 28 Company Quick Takes: Kite, Alkermes, Regeneron-Sanofi, Incyte, NantHealth-NantOmics, Sorrento, MicroCures, Paion-Mundipharma

...research from Albert Einstein College of Medicine. Paion, Mundipharma gain Japan approval Anerem remimazolam from Paion AG...
...Pharmaceuticals Inc. Sanofi Incyte Corp. Interleukin-4 (IL-4) receptor (IL-4R) (IL-4RA) (CD124) Janus kinase-1 (JAK-1) Janus kinase-2 (JAK-2) Mu opioid receptor (MOR) (OPRM1) MicroCures Sorrento FL2 paion...
BioCentury | Jan 5, 2019
Finance

Ready to launch

...data 2H19 Orphazyme A/S (CSE:ORPHA) Arimoclomol Niemann-Pick disease type C Phase II/III final data 1Q19 Paion AG...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...Durect Corp. (NASDAQ:DRRX) Remoxy oxycodone extended release Moderate to severe chronic pain PDUFA date 8/7/18 Paion AG...
BioCentury | Nov 17, 2017
Clinical News

Paion's remimazolam meets in Phase III trial for procedural sedation

...in the double-blind, U.S. trial include time to discharge and recall of procedure. Last year, Paion...
...of Cosmo Pharmaceuticals N.V. (SIX:COPN) exclusive, U.S. rights to develop and commercialize remimazolam. In 2018, Paion...
...A receptor modulator (see BioCentury, July 18, 2016 ). Cosmo Pharmaceuticals N.V. (SIX:COPN), Dublin, Ireland Paion AG...
BioCentury | Jul 18, 2016
Company News

Paion, Cosmo deal

...subsidiary exclusive U.S. rights to develop and commercialize remimazolam, an ultra-short-acting GABA A receptor modulator. Paion...
...the drug’s approval and for approval of additional indications in general anesthesia and ICU sedation. Paion...
...Paion said that Cosmo expects to file a remimazolam NDA at the end of 2017. Paion AG...
BioCentury | Dec 14, 2015
Clinical News

Remimazolam: Phase III started

...midazolam arm will receive a 1 mg initial dose followed by 0.5 mg top-up doses. Paion AG...
BioCentury | Jul 25, 2015
Company News

Management tracks

...Mologen AG (Xetra:MGN) named Mariola Soehngen CEO, effective Nov. 1. Soehngen will remain CMO at Paion AG...
BioCentury | Jun 22, 2015
Clinical News

Remimazolam: Phase III started

...bronchoscopies. Patients will receive 5 mg remimazolam for induction and 2.5 mg top-ups for maintenance. Paion AG...
BioCentury | Apr 13, 2015
Clinical News

Remimazolam: Phase III started

...Pharmaceutical Co. Ltd. , Seoul, South Korea Humanwell Healthcare Group Co. Ltd. (Shanghai:600079), Wuhan, China Paion AG...
Items per page:
1 - 10 of 182